25-OH Vitamin D: When to Order This Test

What Does 25-OH Vitamin D Actually Measure?

The 25-hydroxyvitamin D assay quantifies calcidiol, the primary circulating storage form of vitamin D produced by hepatic hydroxylation of cholecalciferol (D3) or ergocalciferol (D2). This metabolite has a half-life of approximately 15 days, making it the most reliable indicator of total body vitamin D status [1].

Clinicians sometimes confuse this test with the 1,25-dihydroxyvitamin D (calcitriol) assay. That distinction matters. Calcitriol has a half-life of only 4 to 6 hours and is tightly regulated by parathyroid hormone (PTH) and phosphate levels. A patient with severe deficiency can paradoxically show normal or even elevated calcitriol because PTH rises compensatorily, driving renal 1-alpha-hydroxylase activity upward [2]. The Endocrine Society's 2024 clinical practice guideline explicitly states that 25-OH vitamin D is the "preferred measurement for assessing vitamin D status" [3].

Both D2 and D3 metabolites contribute to the total 25-OH vitamin D result. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) differentiates them; most immunoassays report only the combined value. For routine clinical decisions, the total suffices.

Clinical Indications: Who Needs Testing?

Targeted testing in at-risk populations is the standard. The Endocrine Society, AACE, and the National Osteoporosis Foundation all advise against universal population screening but recommend measurement in patients who meet specific criteria [3][4].

Order 25-OH vitamin D when a patient has one or more of the following:

• Osteoporosis, osteopenia, or fragility fracture history
• Chronic kidney disease stage 3 or higher
• Malabsorption syndromes (celiac disease, inflammatory bowel disease, gastric bypass)
• Medications that accelerate vitamin D catabolism (phenytoin, carbamazepine, rifampin, glucocorticoids)
• Obesity with BMI ≥30 (vitamin D sequesters in adipose tissue)
• Dark skin pigmentation with limited UV exposure
• Pregnancy or lactation with inadequate supplementation
• Unexplained hypocalcemia or elevated alkaline phosphatase
• Hyperparathyroidism workup
• Institutionalized or homebound adults
• Granulomatous disease (sarcoidosis, tuberculosis) where 1-alpha-hydroxylase operates extrarenally

The USPSTF in its 2021 recommendation statement found insufficient evidence (I statement) to assess the balance of benefits and harms of screening for vitamin D deficiency in asymptomatic, nonpregnant adults [5]. This does not mean testing has no value. It means the task force could not determine a net benefit for mass screening in people without risk factors.

Normal Ranges and How to Interpret Results

The reference range depends on which guideline you follow. Disagreement persists between professional societies, which creates confusion for patients reading their lab portals.

The Endocrine Society's 2024 guideline defines deficiency as a serum 25-OH vitamin D below 20 ng/mL (50 nmol/L) and insufficiency as 20 to 29 ng/mL (50 to 72 nmol/L) [3]. The Institute of Medicine (now National Academies) set a lower threshold of 20 ng/mL as sufficient for 97.5% of the healthy population's bone needs [6]. AACE and the National Osteoporosis Foundation target 30 ng/mL or above for patients with metabolic bone disease [4].

Practical interpretation for most clinical scenarios:

• Below 12 ng/mL: severe deficiency associated with rickets in children and osteomalacia in adults
• 12 to 20 ng/mL: deficiency; supplement and recheck in 8 to 12 weeks
• 20 to 29 ng/mL: insufficiency in bone-at-risk populations; may be adequate for otherwise healthy adults per IOM
• 30 to 50 ng/mL: target range for patients with osteoporosis, CKD, or malabsorption
• 50 to 100 ng/mL: no additional benefit demonstrated; some labs flag this as "high normal"
• Above 100 ng/mL: potential toxicity; evaluate for hypercalcemia, nephrocalcinosis

A 2022 cross-sectional analysis of NHANES data (2011 to 2018, N=26,010) found that 23.8% of U.S. adults had serum 25-OH vitamin D below 20 ng/mL, with prevalence reaching 39.7% among non-Hispanic Black participants [7].

Timing and Logistics of Specimen Collection

No fasting is required. Draw the sample at any time of day.

Serum is the standard specimen type, though EDTA plasma is acceptable on most platforms. Hemolysis, lipemia, and biotin supplementation above 5 mg/day can interfere with certain immunoassay platforms. If a patient takes high-dose biotin (common in hair and nail supplements), advise them to stop it at least 72 hours before the draw [8].

Seasonal variation is real. A study in Boston (latitude 42°N) showed mean 25-OH vitamin D levels peaked at 33 ng/mL in September and fell to 21 ng/mL in March [9]. For patients borderline in summer, consider that their winter nadir may be clinically relevant. Some clinicians check once in late winter to capture the lowest point.

Turnaround time is 1 to 3 days at Quest, Labcorp, and most hospital labs. Point-of-care immunoassays exist but have higher analytical imprecision (CV 10 to 15% vs. 5 to 8% for LC-MS/MS).

How to Raise 25-OH Vitamin D

Repletion strategy depends on the degree of deficiency. The Endocrine Society recommends 6 to 000 IU daily of vitamin D3 for 8 weeks (or 50 to 000 IU weekly for 8 weeks) in adults with levels below 20 ng/mL, followed by maintenance dosing of 1,500 to 2 to 000 IU daily [3].

Dr. Michael Holick, professor of medicine at Boston University and lead author of the Endocrine Society's 2011 guideline, has stated: "Vitamin D3 is approximately 87% more potent in raising and maintaining serum 25-OH vitamin D concentrations than D2" [10]. This difference reflects D3's higher binding affinity for vitamin D-binding protein and slower hepatic clearance.

For obese patients (BMI ≥30), the Endocrine Society recommends 2 to 3 times the standard dose because of volumetric dilution and adipose sequestration [3]. A randomized trial by Drincic et al. (N=94) confirmed that body weight, not BMI alone, predicted the dose required to reach 30 ng/mL, with a linear relationship of approximately 70 to 80 IU per kilogram of body weight [11].

Practical prescribing notes:

• Cholecalciferol (D3) is preferred over ergocalciferol (D2) for repletion
• Take with a fat-containing meal; absorption increases by roughly 32% compared to fasting [12]
• Magnesium status influences vitamin D metabolism; consider co-supplementation if intake is suboptimal
• Recheck 25-OH vitamin D at 8 to 12 weeks; steady-state requires approximately 3 half-lives (45 days)

Patients with malabsorption (Crohn's disease, celiac, short bowel syndrome) may need intramuscular vitamin D3 (300 to 000 IU single dose) or high-dose oral therapy (50 to 000 IU two to three times weekly) with close monitoring [13].

How to Lower 25-OH Vitamin D

Vitamin D toxicity is rare but real. It does not occur from sun exposure or food sources alone. Virtually all cases stem from over-supplementation with high-dose preparations.

Stop all vitamin D supplements immediately. That is the first intervention.

The mechanism of toxicity is hypercalcemia driven by unregulated intestinal calcium absorption and bone resorption. Symptoms include nausea, vomiting, polyuria, polydipsia, confusion, and in severe cases, renal failure and cardiac arrhythmia [14].

A case series published in the British Medical Journal (2022) reported 12 patients with vitamin D levels ranging from 150 to 640 ng/mL after taking 50,000 to 200 to 000 IU daily for weeks to months [15]. All presented with acute kidney injury. Recovery took 2 to 14 weeks after cessation.

Management of confirmed toxicity:

• Discontinue vitamin D supplementation
• IV normal saline for volume expansion
• Loop diuretics (furosemide) if hypercalcemia is severe (corrected calcium above 14 mg/dL)
• Glucocorticoids (hydrocortisone 200 mg IV or prednisone 40 to 60 mg oral) to reduce intestinal calcium absorption
• Bisphosphonates (zoledronic acid 4 mg IV) for refractory hypercalcemia
• Serial monitoring of calcium, creatinine, and 25-OH vitamin D every 1 to 2 weeks until resolution

Because 25-OH vitamin D is stored in fat, levels decline slowly even after supplementation stops. Half-life in overdose situations can extend to 30+ days.

Special Populations and Testing Frequency

Pregnant patients represent a distinct testing scenario. The American College of Obstetricians and Gynecologists (ACOG) does not recommend universal screening in pregnancy but does endorse testing when risk factors are present [16]. A Cochrane review (2019, 30 trials, N=7,033) found that vitamin D supplementation in pregnancy reduced the risk of pre-eclampsia (RR 0.48 to 95% CI 0.30 to 0.79) and low birthweight (RR 0.55 to 95% CI 0.35 to 0.87) [17].

For chronic kidney disease (CKD), KDIGO 2017 guidelines recommend measuring 25-OH vitamin D at baseline in CKD stages 3 to 5 and correcting deficiency before initiating active vitamin D analogs (calcitriol, paricalcitol) [18]. The rationale is that substrate deficiency limits the kidney's ability to produce calcitriol, and exogenous active vitamin D does not replenish stores.

Patients on anticonvulsants or rifampin should be tested annually. These drugs induce CYP3A4 and CYP24A1, which accelerate 25-OH vitamin D catabolism, sometimes requiring maintenance doses of 4,000 to 6 to 000 IU daily to sustain adequate levels [19].

Bariatric surgery patients (particularly Roux-en-Y gastric bypass) need lifelong monitoring. The American Society for Metabolic and Bariatric Surgery recommends checking 25-OH vitamin D every 3 to 6 months for the first 2 years, then annually [20]. Deficiency prevalence in this group exceeds 50% even with standard supplementation.

When Retesting Adds No Value

Not every patient needs serial measurement. A healthy adult who is already taking 1,000 to 2 to 000 IU daily of vitamin D3, has no risk factors, and has a prior level above 30 ng/mL does not benefit from annual rechecks. The cost and cognitive burden outweigh the clinical yield.

Dr. Clifford Rosen, professor of medicine at Tufts University and a member of the IOM vitamin D committee, noted in a 2014 New England Journal of Medicine editorial: "Routine screening of the general population is not supported by evidence and generates unnecessary cost and anxiety" [21].

The exception: patients whose risk profile changes. New glucocorticoid therapy, a fracture, a diagnosis of celiac disease, significant weight gain, or a move to a high-latitude location all justify repeat testing regardless of prior results.

Assay Variability and Standardization

Not all 25-OH vitamin D assays perform identically. The Vitamin D Standardization Program (VDSP), coordinated by the NIH Office of Dietary Supplements, the CDC, and the National Institute of Standards and Technology (NIST), established reference measurement procedures to reduce inter-laboratory variability [22].

Before standardization efforts began in 2010, proficiency testing surveys showed inter-laboratory CVs of 15 to 25% for the same sample. Post-standardization, most clinical labs achieve <10% CV, but discrepancies still exist between immunoassay platforms and LC-MS/MS, particularly for patients on D2 therapy (some immunoassays underdetect D2 metabolites) [22].

If a patient's result seems discordant with their clinical picture (persistently low despite aggressive supplementation, or unexpectedly high without supplementation), consider repeating with a different methodology. LC-MS/MS at a reference laboratory is the gold standard.

Insurance Coverage and Cost Considerations

Medicare and most commercial payers cover 25-OH vitamin D testing when ordered with a qualifying ICD-10 code. Common covered diagnoses include E55.9 (vitamin D deficiency, unspecified), M81.0 (age-related osteoporosis without fracture), N18.3-N18.5 (CKD stages 3 to 5), and K90.0 (celiac disease).

Without insurance, cash-pay pricing ranges from $30 at direct-to-consumer labs to $75 at hospital outpatient labs. Bundled metabolic panels that include 25-OH vitamin D are available for $50 to $100 at many online lab ordering services.

The test is CPT code 82306. Some payers still require prior authorization for repeat testing within 90 days. Document the clinical rationale in the order note to reduce claim denials.